Amyloid

Hidden Belly Fat in Midlife Linked to Alzheimer's Disease

Retrieved on: 
星期一, 十一月 20, 2023
Connective tissue, Health, RSNA, Woman, Brain, Research, Insulin resistance, Senior, Atrophy, Amyloid, Risk, Protein, Neurology, Obesity, Glucose, MIR, Dementia, Mallinckrodt Institute of Radiology, Radiology, BMI, Diagnosis, Alzheimer's Association, Memory, Communication, Body mass index, MRI, PET, Skin, Society, Inflammation, Radiation, Education, Medical imaging, Alzheimer's disease

Visceral fat is fat surrounding the internal organs deep in the belly.

Key Points: 
  • Visceral fat is fat surrounding the internal organs deep in the belly.
  • Researchers found that this hidden abdominal fat is related to changes in the brain up to 15 years before the earliest memory loss symptoms of Alzheimer's disease occur.
  • The volume of subcutaneous fat (fat under the skin) and visceral fat were measured using abdominal MRI.
  • "This study highlights a key mechanism by which hidden fat can increase the risk of Alzheimer's disease," he said.

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)

Retrieved on: 
星期二, 十一月 7, 2023
MCF, Quality of life (healthcare), HIV disease progression rates, CMP, ID, Amyloid cardiomyopathy, Echocardiography, MRI, MPH, Health, Troponin, Cardiology, Cardiac amyloidosis, GLS, Journal, BWH, University, Patient, N-terminal prohormone of brain natriuretic peptide, Amyloidosis, Heart, LV, Publication, JACC, PET, Quality of life, TBR, Editorial, PET/CT, CAA, Amyloid, Harvard Medical School, ATTR, Devouring Radiant Light, Literature, Alys, Diagnosis, ECV, SAN, Medical imaging, Hospital, AL amyloidosis, Medicine, Iodine, Brigham

124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had negative 99mTc-PYP scans.

Key Points: 
  • 124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had negative 99mTc-PYP scans.
  • The manuscripts from Brigham and Women’s Hospital (BWH) and from the University of Tennessee Graduate School of Medicine were published in the Journal of American College of Cardiology – Cardiovascular Imaging (JACC CV Imaging).
  • The manuscripts, entitled “Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir” and “Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study,” have been published online.
  • These studies suggest that 124I-evuzamitide is a promising novel radiotracer to detect and quantify cardiac amyloid in multiple types of amyloidosis.

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
星期五, 十一月 3, 2023
Amyloid, Financial statement, Luxembourg Centre for Systems Biomedicine, PD, Tax, Target, G&A, AC, Conference, Quarter, PET, University of Luxembourg, AAIC, ALS, KOL, Tau, University, The Michael J. Fox Foundation, Safety, ABATE, Diagnosis, D, CHF, Pharmaceutical industry, Medical imaging

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “As we look to year-end and into 2024, AC Immune is poised to achieve multiple milestones across our clinical programs.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “As we look to year-end and into 2024, AC Immune is poised to achieve multiple milestones across our clinical programs.
  • We remain on track to report safety and immunogenicity data from the AD cohort of our ABATE trial of ACI-24.060 this year.
  • Then, in the first half of 2024 results are anticipated from the important Abeta-PET imaging analyses on amyloid plaque reduction following 6 months of treatment.
  • The Company’s cash balance provides sufficient capital resources to progress into Q4 2024 without considering receipt of potential future milestone payments.

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
星期四, 十一月 2, 2023
Apolipoprotein E, Amyloid, Research, Acute myeloid leukemia, Plaque, Public expenditure, Conference, American Society for Bone and Mineral Research, Society, Osteoporosis, Mouse, ADC, Osteogenesis imperfecta, Annual general meeting, Cancer, Patient, AML, Mineral wool, Pharmaceutical industry, Cryptocurrency

Financial Results for Quarter Ended September 30, 2023

Key Points: 
  • Financial Results for Quarter Ended September 30, 2023
    Cash, cash equivalents, and marketable securities as of September 30, 2023, were $118.2 million as compared to $159.9 million as of December 31, 2022.
  • Research and development expenses were $11.0 million for the quarter ended September 30, 2023, as compared to $13.5 million for the quarter ended September 30, 2022.
  • General and administrative expenses were $4.6 million for the quarter ended September 30, 2023, as compared to $5.7 million for the quarter ended September 30, 2022.
  • Net loss was $14.3 million for the quarter ended September 30, 2023, as compared with a net loss of $18.9 million for the quarter ended September 30, 2022.

Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting

Retrieved on: 
星期四, 十一月 2, 2023
Amyloid, FDA, Standard of care, Headache, IND, International, ATTR, Cardiomyopathy, Diarrhea, CRISPR, Intellia Therapeutics, TTR, Disease, Polyneuropathy, Serum, Amyloidosis, Safety, Therapy, Patient, Back pain, NTLA, Toxic leukoencephalopathy, Pharmaceutical industry, Vaccine

Results were presented in an oral presentation at the 4th International ATTR Amyloidosis Meeting, held Nov. 2–3 in Madrid, Spain.

Key Points: 
  • Results were presented in an oral presentation at the 4th International ATTR Amyloidosis Meeting, held Nov. 2–3 in Madrid, Spain.
  • “With 65 patients reported from the Phase 1 study, this update represents the largest clinical dataset for an in vivo CRISPR-based investigational therapy.
  • These positive interim results add to the growing body of data that demonstrates deep and durable reductions of serum TTR after a single dose of NTLA-2001.
  • The Phase 1 trial is a two-part study evaluating NTLA-2001 in patients with either ATTR amyloidosis with cardiomyopathy (ATTR-CM) or hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).

Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta

Retrieved on: 
星期四, 十一月 2, 2023
University of California, San Diego Performance-Based Skills Assessment, UC San Diego Health, Glaucoma, Therapy, UCSD, Health, Amyloid, Disease, Paratriathlon, University, Eye, Trigeminal ganglion, OCT, Distinguishing, Patient, Diagnosis, Prognosis, Retina, SAN, Medical imaging, Ophthalmology

Glaucoma is an age-related neurodegenerative disease associated with the loss of retinal ganglion cells and characteristic vision loss.

Key Points: 
  • Glaucoma is an age-related neurodegenerative disease associated with the loss of retinal ganglion cells and characteristic vision loss.
  • Converging data indicate that amyloid beta, best known for its association with Alzheimer’s disease, is a key factor in glaucoma pathogenesis.
  • In collaboration with the University of California-San Diego (UCSD), Amydis completed critical proof-of-concept studies demonstrating the Amydis tracers detect amyloid beta in post-mortem human eyes of glaucoma patients, but not healthy subjects.
  • This multi-modal data will include optical coherence tomography (OCT) and OCT Angiography (OCT-A), enabling Amydis to map retinal amyloid beta, retinal structure (OCT), and retinal vascular (OCT-A) signatures and monitor their relative changes to better understand the pathophysiology of glaucoma.

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
星期四, 十一月 2, 2023
Biotechnology, Pharmaceutical, Health, Amyloid, Survival, FDA, Bristol Myers Squibb, Research, Organ dysfunction, AD, IND, PD, Food, VITAL, ATTR, Therapy, Fast track (FDA), AL, Mortality, G&A, Novo Nordisk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Acquisition, European Medicines Agency, American Society of Hematology, MAD, SAD, Orphan, R, TTR, ASH, Clinical trial, Biology, Risk, Alpha-synuclein, Epitope, Amyloidosis, Society, SPA, Patient, Failure, Pharmaceutical industry, Vaccine, Fine chemical, Security (finance), Blood

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.

Key Points: 
  • Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.
  • Robust reduction of brain amyloid plaque has been demonstrated to likely predict clinical benefit for people with early AD.
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for PRX012 for the treatment of AD.
  • As of September 30, 2023, Prothena had $673.1 million in cash, cash equivalents and restricted cash, and no debt.

Alzheon CEO Dr. Martin Tolar to Discuss Positive Results from Phase 2 Biomarker Study and Upcoming Readout from Pivotal APOLLOE4 Phase 3 Study Evaluating Oral ALZ-801/Valiltramiprosate at Truist Securities BioPharma Symposium

Retrieved on: 
星期二, 十月 31, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Amyloid, Czech Institute For International Meetings, AD, Ageing, Plaque, Organic chemistry, CSF, APOE4, MD, Symposium, Genotype, Doctor of Philosophy, Lotte New York Palace Hotel, Cerebrospinal fluid, Truist, Early, Risk, NDA, Safety, Patient, Neurotoxicity, Pharmaceutical industry, Alzheon

Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.

Key Points: 
  • Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.
  • This panel will be moderated by Truist analyst, Robyn Karnauskas, PhD.
  • “Alzheon’s simple oral tablet has the potential to address a large unmet need from both an access and treatment perspective.
  • In addition, Alzheon is collaborating with the Czech Institute of Organic Chemistry & Biochemistry (IOCB) to develop an assay to measure neurotoxic amyloid oligomers in CSF.

Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients

Retrieved on: 
星期三, 十月 25, 2023
Randomness, AD, ADAS, Data, Dementia, Hypoglycemia, Disease, MMSE, Political moderate, Amyloid, Diagnosis, CDR, Patient, Cognition, Insulin, Medical imaging, Pharmaceutical industry

A significant change from baseline was observed in the Amyloid β 42/40 ratio and Amyloid Probability Score as shown by the PrecivityAD® tests from C2N Diagnostics.

Key Points: 
  • A significant change from baseline was observed in the Amyloid β 42/40 ratio and Amyloid Probability Score as shown by the PrecivityAD® tests from C2N Diagnostics.
  • Increased FDG-PET SUVRs were observed in 10 out of 21 patients in a brain imaging sub-study, which is suggestive of reduced amyloid burden.
  • The Company expects to announce unblinded, topline data from this trial in late November or early December.
  • The blinded data presented suggest that NE3107 is a biologically active compound exerting potential effects as observed by biomarker, imaging, cognitive and functional assessments.

Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease

Retrieved on: 
星期三, 十月 25, 2023
Amyloid, Alzheimer's disease, Paper, Dementia, AD, Plaque, Therapy, Neuron, Data, MD, Pathology, IL-6, Cytokine, Doctor of Philosophy, Deficit spending, CNS, McGill University, DSM-IV codes, BDNF, Laboratory, Disease, Caregiver, Neurobiology of Aging, Clinical trial, Rett syndrome, SIGMAR1, Parkinson's disease, Brain, Safety, Patient, Neuroscience, Hippocampus, Central nervous system, Medical device, Pharmaceutical industry, Medical imaging, Ageing

NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, today reported a new peer-reviewed publication in the journal Neurobiology of Aging, titled “Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology”, featuring the orally available small molecule ANAVEX®3-71 (AF710B).1

Key Points: 
  • Preventative treatment with ANAVEX®3-71 reduced levels of insoluble and soluble amyloid-beta as well as plaque deposition in the aging cortex and hippocampus, areas heavily impacted by AD.
  • Notably, the reduction in amyloid pathology was accompanied by a reduction in inflammatory glial activity which is connected to the disease cascade in AD and other dementias.
  • ANAVEX®3-71 treatment downregulated the proinflammatory IL-1β and IL-6 cytokines, which are known to be associated with AD.
  • This long-lasting effect was also observed in previous animal studies of ANAVEX®3-71 at advanced stages of the disease.